Journal article

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020


Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or refractory setting; however, the long-term impact on patient immunology is unknown. In this study, changes in immune subsets of MCL patients treated with combination venetoclax and ibrutinib were assessed over a 4-year period. Multiparameter flow cytometry of peripheral blood mononuclear cells showed that ≥12 months of treatment resulted in alterations in the proportions of multiple immune subsets, most notably CD4+ and CD8+ effector and central memory T cells and natural killer cells, and normalization of T-cell cytokine production in response to T-cell receptor..

View full abstract


Funding Acknowledgements

This study was supported, in part, by the CLL Global Research Foundation, Wilson Centre for Lymphoma Genomics, Snowdome Foundation, and Royal Melbourne Hospital Foundation.